Project Details
PRIME
Biparametric MRI or multiparametric MRI for prostate cancer diagnosis
Status:
Completed
Prospective, international, within-patient, non-inferiority trial that demonstrates that biparametric is non-inferior to multiparametric MRI in the diagnosis of clinically significant and insignificant prostate cancer.
International Collaboration
22
centres
12
countries
Published in JAMA,
2025
Summary
Top Recruting Centres
Awards
RSNA Trainee Research Prize in Genitourinary Imaging (2024)
RSM Urology Section Runner-Up in Professor Geoffrey D. Chisholm CBE Communication Prize (2025)
For patients and public
In centres with high-quality MRI and experienced radiologists, a shorter scan without contrast performs as well as the longer contrast scan. Overall, bpMRI can shorten appointments and remove the need for a cannula, helping more people get the scans they need.
No difference in finding important or unimportant cancers
No increase in the number of men advised to have a biopsy
No differences in false positives / specificity
Only minor differences in treatment decisions
Wish to be involved in contributing to research ideas, please get in touch
compass@ucl.ac.uk
At COMPASS, decade-long research outputs have proven a track record of pioneering surgical standards in prostate and urology care.
©2025, COMPASS Research Group
